Lysine-specific histone demethylase 1A (LSD1) in cervical cancer.
Cervical cancer
DNA methylation
Epigenetic modification
GPER
LSD1
Survival
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
03
05
2020
accepted:
23
07
2020
pubmed:
30
7
2020
medline:
7
10
2020
entrez:
30
7
2020
Statut:
ppublish
Résumé
Demethylation of DNA through enzymes like LSD1 showed a crucial impact on different kind of cancers. Epigenetic modifications in cervical cancer are still not fully investigated nevertheless of high interest for a therapeutic use. Tumor samples of 250 cervical cancer patients were immunochemically stained and evaluated based on Immunoreactive Score. Results were statistically analyzed for clinical and pathological parameters. Our patient collective showed a disadvantage for 10-year survival for patients with a strong expression of LSD1 in the cytoplasm of cervical cancer cells. The results of the correlational analysis further revealed a negative correlation of LSD1 to G-protein coupled estrogen receptor (GPER). Epigenetic changes through enzymes like LSD1 may also be of interest for patients with cervical cancer. A combined therapy with other proteins relayed to cervical cancer like GPER might be of interest for future investigations.
Identifiants
pubmed: 32725356
doi: 10.1007/s00432-020-03338-z
pii: 10.1007/s00432-020-03338-z
pmc: PMC7519903
doi:
Substances chimiques
Biomarkers, Tumor
0
Histone Demethylases
EC 1.14.11.-
KDM1A protein, human
EC 1.5.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2843-2850Références
Nat Rev Cancer. 2011 Sep 23;11(10):726-34
pubmed: 21941284
Breast Cancer. 2017 Sep;24(5):643-657
pubmed: 28601917
Cell. 2004 Dec 29;119(7):941-53
pubmed: 15620353
Acta Cytol. 2020;64(5):420-424
pubmed: 32235115
BMJ. 2015 Jun 30;350:h2372
pubmed: 26126623
Cell Mol Life Sci. 2020 Sep;77(17):3341-3350
pubmed: 32193608
CA Cancer J Clin. 2010 Nov-Dec;60(6):376-92
pubmed: 20959400
Molecules. 2018 Dec 04;23(12):
pubmed: 30518104
Nature. 2012 Feb 01;482(7384):221-5
pubmed: 22297846
Dig Dis Sci. 2013 Jun;58(6):1581-9
pubmed: 23314859
J Cancer Res Clin Oncol. 2014 Apr;140(4):663-71
pubmed: 24515910
Int J Mol Sci. 2017 Aug 05;18(8):
pubmed: 28783064
Curr Opin Cell Biol. 2008 Jun;20(3):316-25
pubmed: 18440794
Front Endocrinol (Lausanne). 2019 Oct 25;10:725
pubmed: 31708873
BMC Cancer. 2017 Aug 31;17(1):606
pubmed: 28859612
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
J Hematol Oncol. 2019 Dec 4;12(1):129
pubmed: 31801559
Biochim Biophys Acta Gene Regul Mech. 2017 Sep;1860(9):905-910
pubmed: 28720390
PLoS One. 2012;7(4):e35065
pubmed: 22493729
Cell Biochem Funct. 2015 Apr;33(3):134-42
pubmed: 25753185
Biochim Biophys Acta. 2013 Oct;1829(10):981-6
pubmed: 23684752
Oncotarget. 2017 Feb 14;8(7):11329-11342
pubmed: 27894088
Int J Mol Sci. 2014 Aug 27;15(9):15161-72
pubmed: 25167139
J Clin Pathol. 2016 Jan;69(1):53-7
pubmed: 26209729
Carcinogenesis. 2005 Dec;26(12):2031-45
pubmed: 16150895
Oncologist. 2004;9(4):361-77
pubmed: 15266090
J Cancer Res Clin Oncol. 2018 Jan;144(1):13-19
pubmed: 28924735
Int J Cancer. 2011 Feb 1;128(3):574-86
pubmed: 20333681
Biomolecules. 2019 Dec 01;9(12):
pubmed: 31805626